iX Biopharma (SGX:42C) has updated its progress on Wafermine and iXB 401, according to a Monday filing on the Singapore Exchange.
Following the end of its licensing agreement with Seelos Therapeutics, iX Biopharma has engaged Kybora, a global life sciences advisory firm, to assist in out-licensing Wafermine, a sublingual ketamine wafer.
Kybora will help the company explore licensing opportunities in key markets for Complex Regional Pain Syndrome (CRPS) and depressive disorders. Wafermine's Orphan Drug Designation from the US FDA emphasizes its potential as a non-opioid treatment option.
The company has also begun preclinical testing for iXB 401, a sublingual semaglutide wafer for Type 2 diabetes and obesity.
iX Biopharma has developed various formulations and appointed a clinical research organization to conduct studies in diabetic mice. iXB 401 aims to improve patient compliance and address supply and environmental challenges associated with current GLP-1 treatments.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。